Randomized clinical trial assessing the effects of Pneumatic Vitreolysis on Vitreomacular traction (Protocol AG),
Role: Investigator,
(07/2019 - 07/2020)
Status: Completed
Single-arm study assessing the effects of Pneumatic Vitreolysis on Macular Hole (Protocol AH),
Role: Investigator,
Status: Completed
Federal
Genetics in retinal diseases project,
Role: PI,
National Eye Institute/NIH/DHHS,
(10/2024 - 10/2025)
Status: Approved
Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD (Protocol AO),
Role: PD/PI,
Jaeb Center for Health Research,
(11/2023 - 12/2024)
Status: Awarded
Intravitreous Anti-VEGF treatment for prevention of vision threatening diabetic retinopathy in eyes at high risk,
Role: PI,
National Eye Institute/NIH/DHHS,
(04/2022 - 04/2023)
Status: Completed
Prompt panretinal photocoagulation versus intravitreal ranibizumab with deferred panretinal photocoagulation for proliferative diabetic retinopathy,
Role: Investigator,
National Eye Institute/NIH/DHHS,
(01/2019 - 01/2020)
Status: Completed
Randomized trial of Intravitreous Aflibercept versus Intravitreous Bevacizumab + deferred Aflibercept for treatment of central-involved diabetic macular edema (Protocol AC),
Role: PI,
National Institute on Minority Health and Health Disparities/NIH/DHHS,
Status: Completed
Vitreous Proteomics in Eyes with a Macular Hole (Protocol AJ),
Role: Investigator,
Jaeb Center for Health Research,
Status: Completed
A phase 2 Evaluation of Tonabersat for Diabetic Macular Edema (Protocol AN),
Role: PI,
Jaeb Center for Health Research,
Status: Completed
For Profit Organization
A prospective, multicenter clinical study of the implantable miniature telescope, model SING in patients with central vision impairment associated with end-stage age-related macular degeneration (AMD),
Role: Investigator,
Samsara Vision, Inc,
(08/2024 - 08/2025)
Status: Approved
A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD),
Role: Investigator,
NGM Biopharmaceuticals, Inc.,
(10/2022 - 10/2023)
Status: Completed
A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of Brolucizumab 6 mg compared to Aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON),
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(08/2022 - 08/2023)
Status: Completed
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema,
Role: Investigator,
Unity Biotechnology, Inc.,
(06/2022 - 06/2023)
Status: Completed
VGFTe-ROP-1920, randomized controlled, multi-center study to assess the efficacy, safety, and tolerability of intravitreal aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity,
Role: Investigator,
Regeneron Pharmaceuticals, Inc.,
(10/2021 - 10/2022)
Status: Completed
An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study,
Role: Investigator,
Regeneron Pharmaceuticals, Inc.,
(01/2021)
Status: Approved
A 12-Month, 2-Arm, randomized, double-masked, multicenter Phase III study assessing the efficacy and safety of Brolucizumab every 4 weeks versus Aflibercept every weeks in adult patients with visual impairment due to Diabetic Macular Edema (KINGFISHER),
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(09/2020 - 09/2021)
Status: Completed
A Phase 2b multicenter dose-ranging study evaluating the safety and efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) compared to Intravitreal Aflibercept in subjects with Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO study),
Role: PI,
Graybug Vision, Inc.,
(09/2020 - 08/2021)
Status: Completed
A phase 2/3, randomized, double-masked, sham-controlled trial of QPI-1007 delivered by single or multi-dose intravitreal injection(s) to subjects with acute nonarteritic anterior ischemic optic neuropathy (NAION),
Role: Investigator,
Quark Pharmaceuticals,
(01/2019 - 01/2020)
Status: Completed
Safety and efficacy of Abicipar Pegol (AGN-150998) in patients with neovascular age-related macular degeneration,
Role: Investigator,
Allergan Inc.,
(09/2018 - 09/2019)
Status: Completed
A 24-week, double-masked, multicenter, two-arm extension study to collect safety and efficacy data on brolucizumab 6 mg drug product intended for commercialization in patients with neovascular age-related macular degeneration who have completed the CRTH258A2301 study,
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(07/2018 - 07/2019)
Status: Completed
A two-year, randomized, double-masked, multi-center, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration,
Role: Investigator,
Alcon Research Inc.,
(02/2018 - 02/2019)
Status: Completed
RAINBOW study: A randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of infants born prematurely with retinopathy of prematurity,
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(02/2018 - 02/2019)
Status: Completed
A multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab (FCFD4514S) in patients with geographic atrophy who have completed Genentech-sponsored lampalizumab studies,
Role: Investigator,
Genentech, Inc.,
(09/2017 - 09/2018)
Status: Completed
Short-term evaluation of combination corticosteroid+anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes (protocol U),
Role: Investigator,
Diabetic Retinopathy Clinical Research Network (DRCRnet),
(04/2017 - 04/2018)
Status: Completed
A phase II, multicenter, randomized, single-masked, sham injection-controlled exposure-response study of lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy,
Role: Investigator,
Genentech, Inc.,
(10/2016 - 10/2017)
Status: Completed
Internal
Effect of Hypochlorous Acid Disinfection on Ocular Flora Prior to Cataract Surgery,
Role: Investigator,
LLU Dept. of Ophthalmology,
(09/2020)
Status: Completed
Collection of vitreous and aqueous samples from patient undergoing vitrectomy and intravitreal injections,
Role: Investigator,
LLU Dept. of Ophthalmology,
(03/2020)
Status: Approved
Anterior chamber depth to axial length ratio as a predictor of post-surgical refractive outcome following uncomplicated cataract surgery,
Role: Investigator,
LLU Dept. of Ophthalmology,
(05/2019)
Status: Approved
Conjunctival floral resistance in a single practice site comparing povidone-iodine prep with or without post-injection second generation fluoroquinolones,
Role: Investigator,
LLU Dept. of Ophthalmology,
(07/2018 - 07/2019)
Status: Completed
Non-Profit Organization
Intravitreous anti-VEGF vs. prompt vitrectomy for vitreous hemorrhage from proliferative diabetic retinopathy (protocol AB),
Role: Investigator,
National Institute for Health Care Management Research and Educational Foundation,
(03/2020 - 03/2021)
Status: Completed